Avelumab and Merkel Cell Carcinoma: Evaluating Causation

Legacy Context: From Environmental Carcinogens to Pharmacovigilance

Historically, the domain of general health and science information has provided a foundational framework for understanding broad disease mechanisms, risk communication, and preventive public health strategies. Within this legacy context, inquiries into cancer causation have typically focused on environmental and occupational exposures, with particular emphasis on known carcinogens such as asbestos and their established links to malignancies like mesothelioma. This heritage has shaped screening recommendations, legal frameworks, and public awareness campaigns that prioritize hazard identification and risk mitigation. Transitioning from this broad health context, the focus now narrows to a specific pharmaceutical exposure scenario: the use of Avelumab, a programmed death-ligand 1 (PD-L1) blocking antibody, in therapeutic settings. While Avelumab is indicated for the treatment of Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer, the question of causation—whether the drug itself may contribute to the development or progression of MCC—represents a distinct occupational and clinical concern. This pivot requires careful consideration of exposure pathways, patient populations, and the pharmacological context, moving from general health literacy toward a targeted evaluation of drug-induced risk. The transition thus reframes the legacy of environmental carcinogen inquiry into a modern pharmacovigilance question, where the exposure is not an industrial toxin but a biologic agent administered under controlled conditions.

Bridge: Avelumab Pharmacology and Clinical Use

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). This narrative examines whether avelumab causes MCC, focusing on clinical presentation, pharmacology, mechanistic pathways, and risk considerations.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC presents as a rapidly growing, painless, firm, dome-shaped nodule, often on sun-exposed skin. Diagnosis is confirmed by histopathology and immunohistochemistry, typically showing expression of cytokeratin 20 and neuroendocrine markers. The disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). In advanced stages, systemic therapy is required, but response to chemotherapy is not durable (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Avelumab Pharmacology and Reported Adverse Effects

Avelumab is an anti-PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune response against cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). Its approval for metastatic MCC was based on the JAVELIN Merkel 200 trial, a two-part, single-arm phase II study. In Part A, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia due to reactivation of sarcoidosis, as described in a case report of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other adverse effects include fatigue, infusion-related reactions, and autoimmune conditions such as pneumonitis, colitis, and hepatitis.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The central question is whether avelumab can cause MCC. The evidence indicates that avelumab is a treatment for MCC, not a cause. The drug is specifically approved for metastatic MCC based on its efficacy in inducing tumor regression (https://pubmed.ncbi.nlm.nih.gov/29799096/). Mechanistically, avelumab enhances the immune system's ability to recognize and destroy MCC cells by blocking PD-L1. There is no evidence in the provided snippets that avelumab induces or promotes the development of MCC. Instead, the drug is used to treat existing MCC. The immune-related adverse events associated with avelumab, such as sarcoidosis reactivation, are distinct from the development of a new malignancy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Furthermore, studies on avelumab-refractory MCC patients show that subsequent treatment with ipilimumab plus nivolumab can be effective, indicating that avelumab does not cause MCC but rather that some patients do not respond to it (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Anchors: Adequacy of Warnings, Causation Considerations, and Timeline

Adequacy of Warnings: The evidence does not discuss specific warnings regarding avelumab and MCC causation. However, given that avelumab is approved for treating MCC, warnings would logically focus on its therapeutic use and potential adverse effects, not on causing the disease. The drug's prescribing information likely includes warnings about immune-related adverse events, but not about inducing MCC. Causation-Related Considerations: For affected patients, the question of causation is moot because avelumab is used to treat MCC, not to cause it. Patients with MCC who receive avelumab are already diagnosed with the disease. The drug's role is therapeutic, and any harm from avelumab would be related to adverse effects, not to causing MCC. The evidence shows that avelumab can lead to immune-related adverse events, but these are manageable, as in the case of hypercalcaemia due to sarcoidosis, which resolved with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Timeline Between Exposure and Documented Harm: The timeline for avelumab's therapeutic effect is typically weeks to months, as seen in clinical trials where responses were assessed over time. For adverse events, such as sarcoidosis reactivation, the timeline can vary. In the reported case, hypercalcaemia occurred during treatment, and avelumab was safely continued after management (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence of a timeline linking avelumab exposure to the development of MCC, as the drug is not a causative agent.

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Instead, it is an effective treatment for metastatic MCC, with response rates of up to 62% for PD-1/PD-L1 inhibition (https://pubmed.ncbi.nlm.nih.gov/36450381/). The drug's mechanism of action involves immune activation against tumor cells, and its adverse effects are immune-related, not carcinogenic. For patients, the risk is not that avelumab causes MCC, but that it may not be effective in some cases, leading to disease progression. Warnings should focus on immune-related adverse events, and causation considerations should center on treatment failure rather than disease induction.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, Avelumab does not cause Merkel Cell Carcinoma. It is a treatment for metastatic MCC, approved based on its efficacy in inducing tumor regression (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug enhances the immune system to fight existing cancer cells, and there is no evidence it induces or promotes MCC development.

What are the adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) such as hypercalcaemia due to sarcoidosis reactivation, fatigue, infusion-related reactions, and autoimmune conditions like pneumonitis, colitis, and hepatitis (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are manageable and do not include causing new malignancies.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.